Topics for today. Issues: Regulatory Obligations Post-marketing Adverse Event Reporting; MDRs and Safety Reports. Post-marketing Submissions
|
|
- Brent Mathews
- 7 years ago
- Views:
Transcription
1 Issues: Regulatory Obligations Post-marketing Adverse Event Reporting; MDRs and Safety Reports Martha A. Feldman, RAC Drug & Device Development Co., Inc. Topics for today Post-approval requirements for drugs (including biotechnology-derived therapeutics), devices and biologics Regulatory Submissions Adverse Events: drugs, devices, biologics Other Post-Marketing Reports Medical Device Reports Safety Reports March 28, March 28, Post-marketing Submissions Supplements , Change in Ownership Adverse Drug Experiences Other Changes and Reports Supplements 21 CFR and Prior approval needed Changes to drug substance or drug product (e.g., relax or delete specs, new analytical methods, new manufacturing methods, &/or facility, components, closure system) Major labeling changes March 28, March 28,
2 Supplements Notification Specifications, methods, facility changes providing tighter controls Labeling that strengthens safety New facility if processes are same and new facility has passed GMP inspection within last 2 years Other Changes/Reports Annual report minor changes Patent information Exception for DNA derived/monoclonal antibodies regulated by FD & C Act: - major changes require a supplement and approval prior to distribution - some other changes require supplement 30 prior to distribution of the changed product March 28, March 28, Change In Ownership Ownership of application may be transferred New and former owners must submit letters Indicate (regulatory) conditions and commitment Adverse Drug Experiences (ADEs) March 28, March 28,
3 FDA Definition of an AE (21 CFR ) Any adverse event associated with the use of a drug in humans, whether or not considered drug-related, related, including the following: an AE occurring in professional practice, an AE occurring from a drug overdose whether or not intentional, an AE occurring from drug abuse, an AE occurring from drug withdrawal, and any failure of expected pharmacological action. ICH Definition of ADR Response to a marketed drug which is noxious and unintended and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of disease or for the modification of physiological function. Recommends the old term side effects no longer be used March 28, March 28, Post-Marketing Study Commitments Conducted after FDA approves a product Especially after an accelerated approval Required of or agreed to by a sponsor Agreement between sponsor and FDA may be reached before or after FDA granted approval Sponsor must file annual reports March 28, Adverse Event Reporting - Drugs Adverse Drug Experiences (21 CFR ) ADEs may be expected (i.e., listed in the labeling) or unexpected; unexpected means AE may be the same as in the labeling but is unusually severe in degree or frequency; includes overdose Review of ADEs: prompt review of ADE reported to sponsor from any source (e.g., commercial marketing experience, post-marketing clinical studies, foreign/domestic, scientific literature, unpublished papers) SOPs required: surveillance, receipt, evaluation, reporting to FDA March 28,
4 Life-Threatening ADE Any ADE that places the patient, in the view of the initial reporter, at immediate risk of death from the ADE as it occurred, i.e., does not include an ADE that, had it occurred in a more severe form might have caused death. Serious Adverse Drug Experience (SADE) Any ADE occurring at any dose that results in one of the following outcomes: death, a life-threatening ADE inpatient hospitalization or prolongation of existing hospitalization, a persistent/significant disability/incapacity, a congenital anomaly/birth/defect March 28, March 28, Unexpected Adverse Drug Reaction (UADE) Any ADE that is not listed in the current labeling for the drug product Includes events that may be related to listed events, but differ because of severity or specificity Review of ADEs Review all ADEs obtained or otherwise received from any source, foreign or domestic, including information derived from: - commercial marketing experience - post-marketing clinical investigations - post-marketing epidemiological/surveillance studies - reports in the scientific literature, and unpublished scientific papers. March 28, March 28,
5 Adverse Drug Experience Reports NOTE: This reporting mechanism does not apply to an ADE occurring g during a post-marketing study; other methods of reporting are done. 15 Day Alert Reports within 15 calendar days of hearing about ADE Alert Reports Follow-up within 15 days of receiving new information Note: retain records for 10 years Periodic Reports Periodic reports quarterly for the 1 st three years, then annually thereafter ADE Information Required date information received and date reported date of occurrence source of report narrative description of event, (include type, severity, frequency) intervention (if required: medical, surgical, etc.) resolution, (or state if ADE is ongoing) causal relationship to drug DO NOT submit patient s s identity March 28, March 28, Safety Reports for Drugs and Biologically-Derived Therapeutics Safety Reports 21 CFR Report on - life threatening ADE - SADE - UADE (ASAP, but no later than 7 calendar days by telephone or FAX) March 28, March 28,
6 Safety Reports (cont.) 21 CFR Finding from tests in lab animals that suggests a significant risk for humans Review safety info IND safety reports - include prior info * Not required of marketed drugs use Med- Watch Medical Product Safety Information FDA Database - Safety Alerts for Drugs, Biologics, Devices and Dietary Supplements Searchable FDA Safety Databases - Vaccine Adverse Event Reporting System (VAERS) - Special Nutritional AE Monitoring System - Manufacturer and User Facility Device Experience Database (MAUDE) March 28, March 28, Medical Product Safety Information (cont. slide 2) Guidance Documents - E2C: E2C: Clinical Safety Data Management, Periodic Safety Update Reports for Marketed Drugs - Addendum IDH E2C: : Draft guideline Medical Product Safety Information (cont. slide 3) Adverse Event Reporting Systems Regulations - 21 CFR Part 7 Recalls - 21 CFR Returned Drug Products - 21 CFR Drug Product Salvaging March 28, March 28,
7 Adverse Experiences - Biologics Adverse Events - Biologics 21 CFR Definition: Any adverse event associated with the use of a biologic in humans, whether or not considered biologic-related, including the following: an AE occurring in professional practice, an AE occurring from an overdose whether or not intentional, an AE occurring from abuse of the biologic material, an AE occurring from withdrawal of the biologic, and any failure of expected biological action. Definition: March 28, March 28, Adverse Experiences: Biologics AEs may be expected (i.e., listed in the labeling) or unexpected; unexpected means AE may be the same as in the labeling but is unusually severe in degree or frequency; includes overdose Review of AEs: prompt review of AE reported to sponsor from any source (e.g., commercial marketing experience, post-marketing clinical studies, foreign/domestic, scientific literature, unpublished papers) SOPs required: surveillance, receipt, evaluation, reporting to FDA AE Reports - Biological Materials NOTE: This reporting mechanism does not apply to an ADE occurring during a post-marketing study; other methods of reporting are done. Timing of reports: within 15 calendar days of hearing about ADE send in a 15-Day Alert Report retain records for 10 years periodic reports quarterly for the first three years, then annually thereafter March 28, March 28,
8 AE Reports - Biological Materials Information required date information received and date reported date of occurrence source of report narrative description of event, (include type, severity, frequency) intervention (if required: medical, surgical, etc.) resolution, (or state if AE is ongoing) name and address of manufacturer DO NOT submit patient s s identity Biological Product Deviation Report (BPDR) Manufacturers report biological deviation that may affect - Safety - Purity - Potency 21 CFT , March 28, March 28, Other Post-marketing Reports for Drugs (314.81) NDA Field Alerts: : within 3 working days to District Office, if drug product is mistaken for another article or contaminated/ deterioration batch failure Annual Reports: : new info on S, E, labeling; distribution data, labeling (summary of changes), CMC changes, update lab, animal & clinical data, status of PM studies Other Post-marketing Reports for Drugs [314.81] (cont) Advertisement & Promotional labeling: - Submit specimens at time of initial distribution/publication March 28, March 28,
9 User Reports Adverse Device Effects Users (healthcare professionals, consumers, etc.) may also file reports (MedWatch) If sponsor is notified by FDA and sent a copy of the User Report, the sponsor does not file a separate report (to avoid duplication at the FDA), but does report on follow-up research and activities. March 28, March 28, Adverse Device Effects Medical Device Effects 21 CFR 803 medical device has/may have caused/contributed to a death or serious injury device has malfunctioned/failed and that malfunction/failure has or may have caused or contributed to a death or serious injury other causes of MDE may be improper or inadequate design, problems in manufacturing, labeling or user error source of reports may be manufacturer, distributor, importer, user, healthcare professional or other semi- professionals Problems Unique to Medical Device Reporting Lack of standard nomenclature for devices These events represent numerators, usually with no clear denominator available Operator involvement and human factors issues inherent in virtually every event Complex multi-device situations are common, leading to complex evaluation March 28, March 28,
10 Device problems - continued Information in reports is often limited MDR may not be be to detect increases in rates of known events Specific disincentives to reporting, e.g., user error MDR not a good method for certain types of products, e.g., IVDs New technology and the learning curve; adequacy of training March 28, Medical Device Reports MedWatch March 28, FDA s s MedWatch Program Mandatory Reporting Manufacturers (bylaw) report deaths and serious injuries or malfunctions (near incidents) if a medical device may have caused or contributed to the event All user facilities (hospitals, nursing homes, etc.) must report deaths to FDA and serious injuries to manufacturers Voluntary reports encouraged from health professionals March 28, March 28,
11 Medical Device Reports Complete a MedWatch form (Form 3500A) Timing of reports User facility: within 10 days of becoming aware of the event Importers : within 30 days Manufacturers within 30 days for an individual event within 5 days if remedial action is needed to prevent unreasonable risk of substantial harm to the public Contents of Form 3500A March 28, March 28, Complaint Regulations Complaints 21 CFR NOTE: MDRs are a subset of complaints Need SOPs: receiving, reviewing, evaluating complaints by a formally designated unit Complaints must be: presented in a uniform and timely manner documented upon receipt (oral or written) evaluated to see if it meets criteria for an MDR (21CFR 803) March 28, March 28,
12 Complaint regulations - cont d Complaints must be evaluated to see if an investigation is needed; if not, document reason Review, evaluate, investigate involving the failure of a device, labeling or packaging to meet any of its specifications If it is reportable as an MDR, the report must be maintained separately, or clearly identified Complaint Regulations - cont d Definition: any expression (written, oral or implied) of dissatisfaction regarding a failure of a product to meet performance specifications or customer expectations Complaints must be reviewed, investigated and documented March 28, March 28, Dietary Supplements Warnings and Safety Info warn.html Veterinary Products Illnesses and Injuries associated with the use of selected dietary supplements March 28, March 28,
13 Remember... For all AE reports, the time begins when any team member* becomes aware of the information * regulatory, clinical, sales, marketing, etc. Questions? Mfeldman@druganddevice.com March 28, March 28,
IOWA STATE UNIVERSITY Institutional Review Board. Reporting Adverse Events and Unanticipated Problems Involving Risks to Subjects or Others
IOWA STATE UNIVERSITY Institutional Review Board Reporting Adverse Events and Unanticipated Problems Involving Risks to Subjects or Others Introduction This policy details the Institutional Review Board
More informationMedical Device Reporting (MDR) 21 CFR Part 803
Medical Device Reporting (MDR) 21 CFR Part 803 1 Objectives Review applicable sections of 21 CFR 803 and 21 CFR 820 Review and explain MDR reporting requirements Review FDA-483 observation examples 2 Medical
More informationST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014
ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014 1. Introduction The St. Michael s Hospital (SMH) REB
More informationMedical Device Reporting. Sharon Kapsch Office of Surveillance and Biometrics Center for Devices & Radiological Health Food & Drug Administration
Medical Device Reporting Sharon Kapsch Office of Surveillance and Biometrics Center for Devices & Radiological Health Food & Drug Administration Session Overview Purpose: To provide information about the
More informationGUIDELINES ON MEDICAL DEVICES
EUROPEAN COMMISSION DG Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Health technology and Cosmetics MEDDEV 2.7/3 revision 3 May 2015 GUIDELINES ON
More informationThe Trans-Tasman Early Warning System. Processes in Australia and New Zealand
The Trans-Tasman Early Warning System Processes in Australia and New Zealand Version 1.0 May 2013 About Medsafe Medsafe is the New Zealand Medicines and Medical Devices Safety Authority and is responsible
More informationPage 191 TITLE 21 FOOD AND DRUGS 355 1
Page 191 TITLE 21 FOOD AND DRUGS 355 1 APPEALS TAKEN PRIOR TO OCTOBER 10, 1962 Section 104(d)(3) of Pub. L. 87 781 made amendments to subsec. (h) of this section inapplicable to any appeal taken prior
More informationICH Topic E 2 A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. Step 5
European Medicines Agency June 1995 CPMP/ICH/377/95 ICH Topic E 2 A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting Step 5 NOTE FOR GUIDANCE ON CLINICAL SAFETY DATA MANAGEMENT:
More informationPOST-APPROVAL SAFETY DATA MANAGEMENT: DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING E2D
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE POST-APPROVAL SAFETY DATA MANAGEMENT: DEFINITIONS
More informationPHARMACOVIGILANCE GUIDELINES
PHARMACOVIGILANCE GUIDELINES What is Pharmacovigilance? Pharmacovigilance is defined as the science and activities concerned with the detection, assessment, understanding and prevention of adverse reactions
More informationIntroduction to Post marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER
Introduction to Post marketing Drug Safety Surveillance: Pharmacovigilance in FDA/CDER LT Andrew Fine, Pharm.D., BCPS Safety Evaluator Division of Pharmacovigilance Office of Pharmacovigilance and Epidemiology
More informationThings You Should Know About Adverse Event Report Data
U.S. Department of Health and Human Services Food and Drug Administration Center for Food Safety and Applied Nutrition CFSAN Adverse Event Reporting System Voluntary Reports on Red Bull Energy Drink January
More informationGuideline on good pharmacovigilance practices (GVP)
1 2 20 February 2012 EMA/876333/2011 3 4 Guideline on good pharmacovigilance practices (GVP) Annex I - Definitions Draft finalised by the Agency in collaboration with Member States 7 February 2012 Definitions
More informationGuidance Notes for Applicants of the Certificate for Clinical Trial on Medical Device
Guidance Notes for Applicants of the Certificate for Clinical Trial on Medical Device List of Contents Page 1. Introduction 1.1 The Medical Device Administrative Control System and the 3 proposed legislation
More informationVertex Investigator-Initiated Studies Program Overview
Vertex Investigator-Initiated Studies Program Overview Our Goal To support independent, investigator-initiated research designed to advance scientific knowledge of disease states, patient populations,
More informationGuidance for Industry Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations
Guidance for Industry Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations DRAFT GUIDANCE This guidance document is being distributed
More informationVigilance Reporting. Vicky Medley - Head of QMS, Medical Devices. September 2015. Copyright 2015 BSI. All rights reserved.
Vigilance Reporting Vicky Medley - Head of QMS, Medical Devices September 2015 2 Why? 3 protecting and improving public health https://www.gov.uk/government/organisations/medicines-and-healthcareproducts-regulatory-agency/about
More informationUnited States Department of Health and Human Services Findings on the Permissibility of Reporting to Public Health Authorities under HIPAA
United States Department of Health and Human Services Findings on the Permissibility of Reporting to Public Health Authorities under HIPAA Background DISCLOSURES FOR PUBLIC HEALTH ACTIVITIES [45 CFR 164.512(b)]
More informationJUL 2 2008. Ms. Kendra Basler Regulatory Affairs Associate Abbott Vascular Cardiac Therapies 3200 Lakeside Drive Santa Clara, CA 95054-2807
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service JUL 2 2008 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Ms. Kendra Basler Regulatory Affairs Associate Abbott Vascular
More informationCDISC Data Standards Can Facilitate Composition of Adverse Event Narratives
CDISC Data Standards Can Facilitate Composition of Adverse Event Narratives Anisa Scott, Ph.D. and Richard C. Zink, Ph.D. JMP Life Sciences SAS Institute, Inc. anisa.scott@jmp.com Copyright 2010 SAS Institute
More informationUS Perspective on the Regulatory Assessment of Benefit-Risk of Vaccines
US Perspective on the Regulatory Assessment of Benefit-Risk of Vaccines Norman W. Baylor Biologics Consulting Group, Inc. 23-25 June 2014 Foundation Merieux Conference Center OUTLINE OF PRESENTATION Introduction
More informationMedical Device Reporting (MDR) Requirements the New FDA Draft Guidance
Medical Device Reporting (MDR) Requirements the New FDA Draft Guidance February 27, 2014 Jeffrey K. Shapiro (202) 737-9633 jshapiro@hpm.com 1 Essential Requirements n Submit MDR reportable events to FDA
More informationMedical Software Development. International standards requirements and practice
Medical Software Development International standards requirements and practice Food and Drug Administration What? A public health agency Why? Protect American consumers How? By enforcing the Federal Food,
More informationFebruary 2006 Procedural
Guidance for Industry Reports on the Status of Postmarketing Study Commitments Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 U.S. Department of Health and
More informationMedicine Safety Glossary
The following definitions are provided as a resource to supplement the information provided in the Medicine Safety Education section of the Pfizer.com Web site; they are not intended as a comprehensive
More informationClinical Trials and Safety Surveillance of Drugs in Development
Clinical Trials and Safety Surveillance of Drugs in Development Hoda Eid, M.Sc., Ph.D. Manager, ADR Unit Office of Clinical Trials Therapeutic Products Directorate hoda_eid@hc-sc.gc.ca Overview Clinical
More informationRoles & Responsibilities of the Sponsor
Roles & Responsibilities of the Sponsor Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Objectives Funding for clinical research comes from
More informationReporting Adverse Events and Concerns at Stroger Hospital
Reporting Adverse Events and Concerns at Stroger Hospital Case Pt on coumadin comes in for community acquired pneumonia and is started on levaquin After several days, you note a lot of bruising.. You realize
More informationAdministrative Policies and Procedures for MOH hospitals /PHC Centers. TITLE: Organization & Management Of Medication Use APPLIES TO: Hospital-wide
Administrative Policies and Procedures for MOH hospitals /PHC Centers TITLE: Organization & Management Of Medication Use APPLIES TO: Hospital-wide NO. OF PAGES: ORIGINAL DATE: REVISION DATE : السیاسات
More informationINSTITUTIONAL POLICY AND PROCEDURE (IPP) Department: Manual: Section:
HOSPITAL NAME INSTITUTIONAL POLICY AND PROCEDURE (IPP) Department: Manual: Section: TITLE/DESCRIPTION POLICY NUMBER OCCURRENCE VARIANCE REPORT SYSTEM EFFECTIVE DATE REVIEW DUE REPLACES NUMBER NO. OF PAGES
More informationSection 5: Quality Systems Regulation (QSR) and Good Manufacturing Practice (GMP)
Section 5: Quality Systems Regulation (QSR) and Good Manufacturing Practice (GMP) 1 Quality Systems Regulation (QSR) 2 Quality Systems Regulation (QSR) and Good Manufacturing Practice (GMP) Sets of checks
More informationGLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group dpifat@bcg-usa.com
GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group dpifat@bcg-usa.com Common Misconception Good Laboratory Practices 1) A quality system concerned with the organizational process
More informationAdverse Events in Clinical Trials: Definitions and Documentation
Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators Adverse Events in Clinical Trials: Definitions
More informationSubject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure
703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a
More informationPHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE
PHARMACY AND POISONS ORDINANCE (Cap. 138) APPLICATION FOR A CLINICAL TRIAL/MEDICINAL TEST CERTIFICATE PART A: TRIAL INFORMATION A1. Title of Clinical Trial (as stated in proposed Protocol) Protocol No.
More informationCombination Products Regulation in the United States
Combination Products Regulation in the United States Presenter: Scott Sardeson RAC US/EU 3M Health Care St. Paul, MN USA 1 Presentation Outline Combination products Definitions and Regulations Jurisdiction
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Page 1 of 7 Home Inspections, Compliance, Enforcement, and Criminal Investigations Compliance Actions and Activities Warning Letters 2014 Inspections, Compliance, Enforcement, and Criminal Investigations
More informationGuidance for Industry
Guidance for Industry Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP U.S. Department of Health and Human Services Food and Drug Administration Center for Drug
More informationGoals & Objectives. Drug Development & the FDA Pharmacy 309. Outline. An History of Disasters. Be able to describe
Drug Development & the FDA Pharmacy 309 Tom Hazlet, Pharm.D., Dr.P.H. 616-2732 thazlet@u... Goals & Objectives Be able to describe the major regulatory events in the drug development process the concepts
More informationOverview of Pre-Approval Inspections
Overview of Pre-Approval Inspections Presented by: Kelli F. Dobilas NWJ-DO Pre-Approval Manager Pre-Approval Drug Inspections What are Pre-Approval Inspections? One of the last reviews of the drug approval
More informationRegulation and Risk Management of Combination Products
Regulation and Risk Management of Combination Products Katherine Ulman Associate Scientist Global Regulatory Compliance Manager Dow Corning Healthcare Jim Curtis Senior Specialist, Healthcare Applications
More informationStudy Start-Up SS-204.01. STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV)
Study Start-Up SS-204.01 STANDARD OPERATING PROCEDURE FOR Site Initiation Visit (SIV) Approval: Nancy Paris, MS, FACHE President and CEO 08 March 2012 (Signature and Date) Approval: Frederick M. Schnell,
More informationChanges to an Approved Product
Changes to an Approved Product Chemistry, Manufacturing and Controls By Khandan Baradaran, PhD and Peggy Berry, MBA, RAC It is a huge achievement for any company to obtain licensing rights to an approved
More informationFDA LACKS COMPREHENSIVE DATA TO DETERMINE WHETHER RISK EVALUATION AND MITIGATION STRATEGIES IMPROVE DRUG SAFETY
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL FDA LACKS COMPREHENSIVE DATA TO DETERMINE WHETHER RISK EVALUATION AND MITIGATION STRATEGIES IMPROVE DRUG SAFETY Daniel R. Levinson Inspector
More informationHealth Products and Food Branch. www.hc-sc.gc.ca
Health Products and Food Branch 1 HEALTH CANADA PART C DIVISION 5 - DRUGS FOR CLINICAL TRIALS INVOLVING HUMAN SUBJECTS Part C - Division 5 2 Part A: Part B: Part C: Part D: Part E: Part G: Part J: Administration
More informationGuidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events
Office for Human Research Protections (OHRP) Department of Health and Human Services (HHS) Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events
More informationGENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):
Make copies of the blank SAE report form as needed. Retain originals with confirmation of all information faxed to DMID Pharmacovigilance Group Clinical Research Operations and Management Support (CROMS
More informationRegulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective
Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective Office of Vaccines Research and Review Center for Biologics Evaluation and Research U.S. Food
More informationLibrary Guide: Pharmaceutical GMPs
Library Guide: Pharmaceutical GMPs Table of Contents Overview...3 Courses Listed by Functional Area... 4 Course Descriptions: A Step-by-Step Approach to Process Validation (PHDV79)... 7 A Tour of the FDA
More informationCHAPTER 7 - RECALL ACTIVITIES
CHAPTER 7 INVESTIGATIONS OPERATIONS MANUAL 2015 CONTENTS CHAPTER 7 - RECALL ACTIVITIES 7.1.1.1 - Recall SUBCHAPTER 7.1 - RECALLS... 368 7.1.1 - DEFINITIONS... 368 7.1.1.1 - Recall... 368 7.1.1.2 - Recall
More informationPost-Approval Change Management: Challenges and Opportunities An FDA Perspective
CMC Workshop From Drug Development to Global Supply to Patients April 15-17, 2013, Washington, DC Post-Approval Change Management: Challenges and Opportunities An FDA Perspective Christine M. V. Moore,
More informationGuidance for Clinical Investigators, Sponsors, and IRBs
Guidance for Clinical Investigators, Sponsors, and IRBs Adverse Event Reporting to IRBs Improving Human Subject Protection U.S. Department of Health and Human Services Office of the Commissioner (OC) Center
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/CVMP/044/99-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT
More informationQuality Agreements: Contractual Commitments by CROs to Deliver High-Quality Work
Vol. 10, No. 11, November 2014 Happy Trials to You Quality Agreements: Contractual Commitments by CROs to Deliver High-Quality Work By Tom McGrady and Susan Callery-D Amico Introduction Regulated companies
More informationPreparing for the Pre-Approval Inspection What to do Before the FDA Arrives. Barry A. Friedman, Ph.D. Consultant
Preparing for the Pre-Approval Inspection What to do Before the FDA Arrives Barry A. Friedman, Ph.D. Consultant FDA Overview FDA is a consumer protection agency within the Department of Health & Human
More informationG. Recalls. http://www.fda.gov/safety/recalls/industryguidance/ucm129259.htm.
G. Recalls 1. Background When an FDA-regulated product is defective, potentially harmful, or mislabeled, recalling that product removing it from the market or correcting the problem is often the most effective
More informationConducting a Gap Analysis on your Change Control System. Presented By Miguel Montalvo, President, Expert Validation Consulting, Inc.
Conducting a Gap Analysis on your Change Control System Presented By Miguel Montalvo, President, Expert Validation Consulting, Inc. Standards, Regulations, Guidelines related to Change Control Management
More informationLaurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute
Laurie Shaker-Irwin, Ph.D., M.S. Co-Leader, Regulatory Knowledge and Research Ethics UCLA Clinical and Translational Science Institute Understand the protocol completely Recognize institutional polices
More informationORACLE CONSULTING GROUP
ORACLE CONSULTING GROUP An Official United States Agent Firm for Foreign Establishments CONSULTING MEMORANDUM: DEALING WITH A MEDICAL DEVICE IN THE U.S. 5398 Golder Ranch Rd., Ste. 1 Tucson, Arizona 85739
More informationUW School of Dentistry Comprehensive Medication Policy
UNIVERSITY OF WASHINGTON SCHOOL OF DENTISTRY Subject: UW School of Dentistry Comprehensive Medication Policy Policy Number: Effective Date: December 2014 Revision Dates: June 2015 PURPOSE This policy provides
More informationSCHOOL OF PUBLIC HEALTH. HIPAA Privacy Training
SCHOOL OF PUBLIC HEALTH HIPAA Privacy Training Public Health and HIPAA This presentation will address the HIPAA Privacy regulations as they effect the activities of the School of Public Health. It is imperative
More informationCorrections and Removals 21 CFR Part 806
Corrections and Removals 21 CFR Part 806 Presented by: Kimberly Lewandowski-Walker Food and Drug Administration Division of Domestic Field Investigations Office of Regulatory Affairs From the Newsroom
More informationEffective Date: October 2015
University of Maryland Greenebaum Cancer Center UMGCC Standard Operating Procedure Title: Data & Safety Monitoring Plan Effective Date: October 2015 Procedure No: DSM001 University of Maryland Greenebaum
More informationBuprenorphine-containing Transmucosal products for Opioid Dependence (BTOD) Risk Evaluation and Mitigation Strategy (REMS)
Initial REMS approval: 02/2013 Most recent modification: 06/2015 Buprenorphine-containing Transmucosal products for Opioid Dependence (BTOD) Risk Evaluation and Mitigation Strategy (REMS) This REMS applies
More informationHealth Canada s GCP Compliance Program. GCP Information Sessions November 2010
Your Health and Safety... Our priority Votre santé et votre Securité notre priorité Health Canada s GCP Compliance Program GCP Information Sessions November 2010 Objective To describe the role that Health
More informationLEBANESE MINISTRY OF HEALTH DIRECTIVE
LEBANESE MINISTRY OF HEALTH DIRECTIVE LAYING DOWN DETAILED GUIDELINES FOR SPONSORS OF CLINICAL TRIALS March 2012 Field of Application General Considerations Trial s submission Validity of the F-MRI opinion
More informationGxP Process Management Software. White Paper: Ten Most Common Reasons for FDA 483 Observations and Warning Letter Citations
GxP Process Management Software : Ten Most Common Reasons for FDA 483 Observations and Warning Letter Citations Most FDA violations involve one of the following: Not having procedures in a regulated area
More informationMedical Device Reporting for User Facilities
Medical Device Reporting for User Facilities DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Food and Drug Administration Medical Device Reporting for User Facilities Prepared by Office
More informationExpanded Access Programs. Richard Klein Office of Special Health issues Food and Drug Administration
Expanded Access Programs Richard Klein Office of Special Health issues Food and Drug Administration Expanded Access Programs (EAPs) What is expanded access? History Legislative background General principles
More informationOVERVIEW OF THE PREQUALIFICATION OF DIAGNOSTICS ASSESSMENT PROCESS. Prequalification of Diagnostics
D i a g n o s t i c s a n d L a b o r a t o r y T e c h n o l o g y OVERVIEW OF THE PREQUALIFICATION OF DIAGNOSTICS ASSESSMENT PROCESS Prequalification of Diagnostics PQDx_007 v3 20 April 2010 Table of
More informationRisk Management in the Pharmaceutical Industry. Elena Apetri, Global Medical Safety Surveillance Schering AG
Risk Management in the Pharmaceutical Industry Elena Apetri, Global Medical Safety Surveillance Schering AG Topics Environment Safety Risk Management Guidance Safety RM Systems Signal detection and evaluation
More informationWHITEPAPER: SOFTWARE APPS AS MEDICAL DEVICES THE REGULATORY LANDSCAPE
WHITEPAPER: SOFTWARE APPS AS MEDICAL DEVICES THE REGULATORY LANDSCAPE White paper produced by Maetrics For more information, please contact global sales +1 610 458 9312 +1 877 623 8742 globalsales@maetrics.com
More informationThis document is meant purely as a documentation tool and the institutions do not assume any liability for its contents
2001L0020 EN 07.08.2009 002.001 1 This document is meant purely as a documentation tool and the institutions do not assume any liability for its contents B DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENT
More informationFAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE
FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE Marion Gruber, Ph.D. Director Office of Vaccines Research & Review Center for Biologics Evaluation and Research US Food and Drug Administration
More informationFDA Fast Track and Priority Review Programs
Order Code RS22814 February 21, 2008 FDA Fast Track and Priority Review Programs Summary Susan Thaul Specialist in Drug Safety and Effectiveness Domestic Social Policy Division By statutory requirements
More informationCosmetics Safety Bill Would Incorporate TSCA Bill Provisions
Beveridge & Diamond, P.C., August 2, 2010 Regulation of cosmetics by the Food and Drug Administration ( FDA ) would be thoroughly overhauled under a bill introduced on July 20, 2010, the Safe Cosmetics
More informationRisk Management Plan (RMP) Guidance (Draft)
Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Translated by Pharmaceuticals and Medical Devices Agency Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour
More informationGENERAL INSTRUCTIONS
GENERAL INSTRUCTIONS All entries should be typed or printed in a font no smaller than 8 point. Complete all sections that apply. If information is unknown, not available or does not apply, the section
More informationTYSABRI Risk Management Plan. Carmen Bozic, MD Vice President Drug Safety and Risk Management Biogen Idec Inc
76 TYSABRI Risk Management Plan Carmen Bozic, MD Vice President Drug Safety and Risk Management Biogen Idec Inc 77 Presentation Outline Overview and Goals of Plan Risk Minimization Plan Risk Assessment
More information11/10/2011. History of CBUs. 10-CBA providing access to unlicensed cord blood units. The FDA s involvement. The FDA s involvement, cont.
History of CBUs First CBU transplant done in 1988 10-CBA providing access to unlicensed cord blood units Using the NMDP IND to access unlicensed cord blood units Amy Hays, Sr. Clinical Research Specialist,
More informationOverview of Drug Development: the Regulatory Process
Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Adapted from course taught by Cato Research Background: Roger
More informationTRANSATLANTIC TRADE AND INVESTMENT PARTNERSHIP
DISCLAIMER: The EU reserves the right to make subsequent modifications to this text and to complement its proposals at a later stage, by modifying, supplementing or withdrawing all, or any part, at any
More informationManaging Risk in Clinical Research. Dr Martha J Wrigley R&D Manager Senior Visiting Fellow University of Surrey
Managing Risk in Clinical Research Dr Martha J Wrigley R&D Manager Senior Visiting Fellow University of Surrey Aim of the session To explore the risks associated with clinical research and understand how
More informationGlossary of terms used in Pharmacovigilance
Glossary of terms used in Pharmacovigilance Absolute risk Risk in a population of exposed persons; the probability of an event affecting members of a particular population (e.g. 1 in 1,000). Absolute risk
More informationPHARMACEUTICAL QUALITY SYSTEM Q10
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE PHARMACEUTICAL QUALITY SYSTEM Q10 Current Step
More informationTexas Tech University Health Sciences Center-El Paso. Medical Equipment Management Plan
Texas Tech University Health Sciences Center-El Paso Medical Equipment Management Plan Medical Equipment Management Plan Contents I. Objective and Purpose II. III. IV. Selection and Acquisition Equipment
More informationHaving regard to the Treaty establishing the European Community, and in particular Article 95 thereof,
L 121/34 DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to
More informationData Management & Case Report Form Development in Clinical Trials. Introduction to the Principles and Practice of Clinical Research.
Data Management & Case Report Form Development in Clinical Trials Introduction to the Principles and Practice of Clinical Research February 3, 2015 Marge Good, RN, MPH, OCN Nurse Consultant Division of
More informationRAC (US) Examination Study Checklist
RAC (US) Examination Study Checklist Instructions: Use this checklist to track your progress when preparing for the RAC (US) certification examination. When you begin your studying, each task statement
More informationComparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE
Comparative analysis between the possible regulatory approaches to GMP compliance TITOLO PRESENTAZIONE Dr. Fulvio CARLOTTI, GNOSIS SpA, Corporate QA Director September 26, 2014 Scope of GMP GMP compliance
More informationStandards of Practice for Pharmacists and Pharmacy Technicians
Standards of Practice for Pharmacists and Pharmacy Technicians Introduction These standards are made under the authority of Section 133 of the Health Professions Act. They are one component of the law
More informationRegulator s Role in GCP
Regulator s Role in GCP David A. Lepay, M.D., Ph.D. APEC GCP Inspection Workshop May 27, 2008 Objectives of this Talk Review the roles and responsibilities of the regulatory authority under GCP Identify
More informationPremarket Approval Applications (PMAs), Product Development Protocols (PDPs), and Humanitarian Device Exemptions
FDLI s Introduction to Medical Device Law and Regulation: Understanding How FDA Regulates the Medical Device Industry October 28-29, 2002 The Westin Grand Hotel Washington, D.C. Premarket Approval Applications
More informationMaking SOP Training More Effective
By David Peterson, Director, GMP and Quality Systems, UL EduNeering SOPs are critical to efficient operations, quality control and regulatory compliance. This paper reviews best practices for the Life
More informationLearn More About Product Labeling
Learn More About Product Labeling Product label The product label is developed during the formal process of review and approval by regulatory agencies of any medicine or medical product. There are specific
More informationRESOLUTION - RDC NO. 23, FROM APRIL 4, 2012
RESOLUTION - RDC NO. 23, FROM APRIL 4, 2012 It addresses the compulsory execution and notification of field actions by the registration holders for health products in Brazil. The Collegiate Director Board
More informationData Management in Clinical Trials
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research February 19, 2013 Diane St. Germain, RN, MS Nurse Consultant Division of Cancer Prevention National Cancer
More informationGuideline for Industry
Guideline for Industry The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Longterm Treatment of Non-Life- Threatening Conditions ICH-E1A March 1995 GUIDELINE FOR INDUSTRY
More informationCONDUCTING GLOBAL CLINICAL RESEARCH TRIALS:
CONDUCTING GLOBAL CLINICAL RESEARCH TRIALS: COMPARING AND CONTRASTING FDA MEDICAL DEVICE REGULATIONS FOR CLINICAL INVESTIGATORS WITH ISO 14155:2011 Introduction Today s clinical research landscape for
More informationA New Standard for Medical Device Adverse Event Classification
Vol. 5, No. 12, December 2009 Can You Handle the Truth? A New Standard for Medical Device Adverse Event Classification By Nancy J. Stark Adverse events are defined and managed differently in the device
More information